Corporate Venture "Parents" Rarely Buy Or Partner With Biotech Investments
This article was originally published in Start Up
Based on a five-year analysis of the biopharma investments of SR One, Novartis Venture Funds, and Johnson & Johnson Development Corp., the "parent" entities of these CVC arms rarely, if ever, forge partnerships with their biotech portfolios.
You may also be interested in...
Working on an allosteric ACC inhibitor in NASH, Nimbus is not worried about being first to market but is willing to let others develop and prove out a pivotal development pathway in the indication, while it focuses on a unique mechanism of action.
In our 11th annual analysis of Series A financings, we look at five sub-species of A round investors, their habits, habitats, and behaviors during 2014.
New data show that including one or more corporate venture investors in a syndicate actually translates into a higher median step-up valuation.